Scancell Holdings (GB:SCLP) has released an update.
Scancell Holdings plc has announced the MHRA’s approval to include an additional cohort in its ModiFY cancer trial, using its Modi-1 vaccine in conjunction with a combination of checkpoint inhibitors to treat untreated renal cell carcinoma patients. The expansion is supported by promising early data from the Modi-1 monotherapy, highlighting its safety and potential in improving treatment responses. This development is a significant step for Scancell, suggesting a potential paradigm shift in treating renal and other challenging cancers.
For further insights into GB:SCLP stock, check out TipRanks’ Stock Analysis page.
